FDA Approves FENOFIBRATE — Bostal LLC
The FDA has granted approval to Bostal LLC for the ANDA/Fenofibrate application (ANDA208476), marking the arrival of a generic version of fenofibrate. The approval of this oral drug is expected to immediately intensify price competition in the lipid-lowering market, pressuring existing branded formulations and driving significant savings for end payors.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed